Sei Investments Co. lifted its position in Flexion Therapeutics Inc (NASDAQ:FLXN) by 1,750.1% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 38,168 shares of the specialty pharmaceutical company’s stock after purchasing an additional 36,105 shares during the period. Sei Investments Co. owned 0.10% of Flexion Therapeutics worth $987,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Rubric Capital Management LP boosted its holdings in shares of Flexion Therapeutics by 108.6% in the first quarter. Rubric Capital Management LP now owns 2,023,704 shares of the specialty pharmaceutical company’s stock valued at $45,351,000 after purchasing an additional 1,053,704 shares during the period. Millennium Management LLC purchased a new stake in shares of Flexion Therapeutics in the first quarter valued at approximately $15,511,000. Peregrine Capital Management LLC boosted its holdings in shares of Flexion Therapeutics by 5.4% in the second quarter. Peregrine Capital Management LLC now owns 666,160 shares of the specialty pharmaceutical company’s stock valued at $17,220,000 after purchasing an additional 33,890 shares during the period. Wasatch Advisors Inc. boosted its holdings in shares of Flexion Therapeutics by 2.4% in the second quarter. Wasatch Advisors Inc. now owns 647,931 shares of the specialty pharmaceutical company’s stock valued at $16,749,000 after purchasing an additional 15,260 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Flexion Therapeutics by 1.3% in the first quarter. Northern Trust Corp now owns 426,469 shares of the specialty pharmaceutical company’s stock valued at $9,558,000 after purchasing an additional 5,451 shares during the period. Hedge funds and other institutional investors own 99.10% of the company’s stock.

A number of analysts recently issued reports on FLXN shares. BidaskClub upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 14th. Benchmark started coverage on Flexion Therapeutics in a report on Thursday, June 28th. They issued a “buy” rating and a $39.00 price target for the company. ValuEngine lowered Flexion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 27th. Finally, Zacks Investment Research upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $91.50.

Shares of NASDAQ:FLXN opened at $22.09 on Wednesday. The company has a market capitalization of $828.16 million, a P/E ratio of -5.31 and a beta of 0.72. Flexion Therapeutics Inc has a 52 week low of $19.06 and a 52 week high of $32.25. The company has a quick ratio of 12.78, a current ratio of 12.90 and a debt-to-equity ratio of 0.80.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($1.16) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.06. The business had revenue of $3.80 million during the quarter, compared to the consensus estimate of $3.96 million. sell-side analysts predict that Flexion Therapeutics Inc will post -4.75 EPS for the current fiscal year.

In other Flexion Therapeutics news, CEO Michael D. Clayman purchased 10,000 shares of Flexion Therapeutics stock in a transaction dated Thursday, August 9th. The shares were acquired at an average cost of $22.33 per share, with a total value of $223,300.00. Following the completion of the transaction, the chief executive officer now owns 75,282 shares in the company, valued at approximately $1,681,047.06. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Neil Bodick sold 50,000 shares of the company’s stock in a transaction on Tuesday, July 3rd. The stock was sold at an average price of $25.07, for a total value of $1,253,500.00. The disclosure for this sale can be found here. Insiders own 14.59% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Further Reading: Closed-End Mutual Funds (CEFs)

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.